Characterization of human hybridoma clones isolated from hemophilia patients with specificity for different domains of coagulating factor VIII

Human Antibodies

Volumn 12, Issue 3, 2003, Pages 67-76

  Gharagozlou, S ^a,b   Ghods, R ^a,c   Samadi Bahrami, Z ^b   Roohi, A ^a   Jeddi Tehrani, M ^c,d   Conti Fine, B M ^e   Sharifian, R A ^a   Rabbani, H ^c,d   Shokri, F ^a,b,c  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b PASTEUR INSTITUTE OF IRAN   (Iran)

^c Avesina Research Center   (Iran)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Cross reactive idiotype; Factor VIII; Hemophilia A; Human hybridoma; Inhibitor; Monoclonal antibody; VH gene

Indexed keywords

BLOOD CLOTTING FACTOR 8 ANTIBODY; IMMUNOGLOBULIN; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; IMMUNOGLOBULIN M ANTIBODY; MONOCLONAL ANTIBODY; THROMBIN;

ADULT; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; CASE REPORT; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HEMOPHILIA; HUMAN; HYBRIDOMA; IMMUNOBLOTTING; LYMPHOBLASTOID CELL LINE; LYMPHOCYTE; MALE; MOLECULAR CLONING; MULTIGENE FAMILY; MYELOMA; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0345257725     PISSN: 10932607     EISSN: None     Source Type: Journal    
DOI: 10.3233/hab-2003-12303     Document Type: Article

References (48)

1. L.W. Hoyer, Why do many hemophilia A patients develop an inhibitor? Br J Haematol 90 (1995), 498-501.
2. C.R.M. Hay, Why do inhibitors arise in patients with hemophilia A? Br J Haematol 105 (1999), 584-590.
3. S. Ehrenforth, W. Kreuz and I. Scharrer et al., Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs, Lancet 339 (1992), 594-598.
4. R.K. Pruthi and W.L. Nicholas, Autoimmune factor VIII inhibitors, Curr Opin Haematol 6 (1999), 314-322.
5. E.L. Saenko, M. Shima and A.G. Sarafanov, Role of activation of the coagulation factor VIII in interaction with von Willebrand factor, phospholipid, and functioning within the factor Xase complex, Trends Cardiovasc Med 9 (1999), 185-192.
6. P.J. Lenting, J.A. Van Marik and K. Mertens, The life cycle of coagulation factor VIII in view of its structure and function, Blood 92 (1998), 3983-3996.
7. W.I. Wood, D.J. Capon and C.C. Simonsen et al., Expression of active human factor VIII from recombinant DNA clones, Nature 312 (1984), 330-337.
8. C. Fulcher, S. De Graaf Mahoney and T. Zimmerman, Factor VIII inhibitor IgG subclass and FVIII polypeptide specificity determined by immunoblotting, Blood 69 (1987), 1475-1480.
9. J.G. Gilles, J. Arnout, J. Vermylen and J.M.R. Saint-remy, Anti-factor VIII antibodies of haemophiliac patients are frequently directed towards nonfunctional determinants and do not exhibit isotypic restriction, Blood 82 (1993), 2452-2461.
10. C. Fulcher, S. De Graaf Mahoney, J. Roberts, C. Kaspe and T. Zimmerman, Localization of human FVIII inhibitor epitopes to two polypeptide fragments, Proc Natl Acad Sci USA 82 (1985), 7728-7732.
11. D. Scandella, S. De Graaf Mahoney, M. Mattingly, D. Roeder, L. Timmons and C. Fulcher, Epitope mapping of human FVIII inhibitor antibodies by deletion analysis of FVIII fragments expressed in Escherichia Coli, Proc Natl Acad Sci USA 85 (1988), 6152-6156.
12. E.L. Saenko and D. Scandella, The acidic region of the factor VIII light chain and the C2 domain together form a high affinity binding site for von Willebrand factor, J Biol Chem 272 (1997), 18007-18014.
13. E.L. Saenko, M. Shima, K.J. Rajalakshima and D. Scandella, A role for the C2 domain of factor VIII in binding to von Willlebrand factor, J Biol Chem 269 (1994), 11601-11605.
14. E.L. Saenko, M. Shima, G. Gilbert and D. Scandella, Slowed release of thrombin-cleaved factor VIII from von Willebrand factor by a monoclonal and a human antibody is a novel mechanism for factor VIII inhibition, J Biol Chem 271 (1996), 27424-27431.
15. P.J. Fay, T. Beattie, C.F. Huggins and L.M. Regan, Factor Villa A2 subunit residues 558-565 represent a factor IXa interactive site, J Biol Chem 269 (1994), 20522-20527.
16. M.G. Jacquemin, B.G. Desqueper, A. Benhida et al., Mechanism and kinetics of factor VIII inactivation: Study with an IgG4 monoclonal antibody derived from a hemophilia A patient with inhibitor, Blood 92 (1998), 496-506.
17. M.G. Jacquemin, A. Benhida and K. Peerlink et al., A human antibody directed to the factor VIII Cl domain inhibits factor VIII cofactor activity and binding to von Willebrand factor, Blood 95 (2000), 156-163.
18. HIII-associated cross-reactive idiotype on human B-lymphocytes: Association with staphylococcal protein A (SPA) binding and staphylococcus aureus Cowan I (SAC) stimulation, J Immunol 146 (1991), 936-940.
19. C.K. Kasper, L.M. Aledort and D. Aronson et al., A more uniform measurement of factor VIII inhibitors, Thromb Diath Haemorrh 34 (1975), 869-871.
20. G. Tosato and R.M. Blaese, Epstein-Barr virus infection and immunoregulation in man, Adv Immunol 37 (1985), 99-149.
21. R. Payam khaja Pasha, A. Roohi and F. Shokri, Establishment of heterohybridoma and lymphoblastoid cell lines specific for the Rh D and C antigens, Transfusion Medicine 13 (2003), 83-92.
22. F. Shokri, R.A. Mageed and R. Jefferis, A quantitative ELISA for measurement of RF-associated CRI in serum from patients with rheumatic disease, Br J Rheum 32 (1993), 862-869.
23. H1 subgroup in CD5 expressing B lymphocytes from patients with chronic lymphocytic leukemia (B-CLL), Scan J Immunol 85 (1991), 20-27.
24. F.K. Stevenson, G.J. Smith, J. North, T.J. Hamblin and M.J. Glennie, Identification of normal B-cells counterparts of neo-plastic cells which secret cold agglutinins of anti-I specificity, Br J Haematol 72 (1989), 9-15.
25. M. Ono, C.G. Winearls and N. Amos et al., Monoclonal antibodies to restricted and cross-reactive idiotypes on monoclonal RF and their recognition of idiotype-positive cells, Eur J Immunol 17 (1987), 343-349.
26. H6-encoded IgM antibodies in early ontogeny, J Immunol 150 (1993), 1-8.
27. R.A. Mageed, M.R. Walker and R. Jefferis, Restricted light chain subgroup expression on human rheumatoid factor para-proteins determined by monoclonal antibodies, Immunology 59 (1986), 473-478.
28. R.E. Schrohenloher, M.A. Accavitti, A.S. Bhown and W.J. Koopman, Monoclonal antibody 6B6.6 defines a cross-reactive kappa light chain idiotope on human monoclonal and polyclonal rheumatoid factors, Arth Rheum 33 (1990), 187-198.
29. D.A. Carson and S. Fong, A common idiotype on human rheumatoid factors identified by a hybridoma antibody, Mol Immunol 20 (1983), 1081-1087.
30. R Shokri, R.A. Mageed and B.R. Maziak, Lymphoproliferation in primary Sjogren's syndrom: Evidence of selective expansion of a B cell subset characterized by the expansion of cross-reactive idiotypes, Arth Rheum 36 (1993), 1128-1136.
31. P. Willems, O. Verhagen and C. Segeren et al., Consensus strategy to quantitate malignant cells in myeloma patients is validated in a multicenter study. Belgium-Dutch Hematology-Oncology Group, Blood 96 (2000), 63-70.
32. HDJH gene sequences and antigen reactivity of monoclonal antibodies produced by human B-1 cells: evidence for somatic selection, J Immunol 158 (1997), 2477-2489.
33. W.G. Niedbala and D.I. Stott, A comparison of three methods for production of human hybridomas secreting auto-antibodies, Hybridoma 17 (1998), 229-304.
34. J.M. Lavergne, D. Meyer and H. Reisner, Characterization of human anti-factor VIII antibodies purified by immune complex formation, Blood 48 (1976), 931-939.
35. M.A. Shokrgozar and F. Shokri, Enumeration of hepatitis B surface antigen-specific B-lymphocytes in responder and non-responder normal individuals vaccinated with recombinant hepatitis B surface antigen, Immunology 104 (2001), 75-79.
36. M. Torica, L. Bracei-laudiero and M. Lucibello et al., Nerve growth factor is an autocrine survival factor for memory B-lymphocytes, Cell 85 (1996), 345-356.
37. M.K. Slifka and R. Ahmed, Long-lived plasma cells: a mechanism for maintaining persistent antibody production, Curr Opin Immunol 10 (1998), 252-258.
38. J.J. Toole, J.L. Knopf and J.M. Wozney et al., Molecular cloning of a cDNA encoding human antihaemophilic factor, Nature (London) 312 (1984), 342-347.
39. D. Scandella, Epitope specificity and inactivation mechanisms of FVIII inhibitor antibodies, Vox Sang 77 (Suppl 1) (1999), 17-20.
40. H repertoire, Immunol Today 16 (1995), 237-242.
41. H and VK germline genes, Int Immunol 9 (1997), 1801-1815.
42. H1 germline genes, Blood 95 (2000), 558-563.
43. K. Rajewsky, Clonal selection and learning in the antibody system, Nature (381) (1996), 751-758.
44. E.N. Van den Brink, E.A.M. Urenhout, C.M.C. Bank, K. Fijnvandraat, M. Peters and J. Voorberg, Molecular analysis of human anti-factor VIII antibodies by V gene phage display identifies a new epitope in the acidic region following the A2 domain, Blood 96 (2000), 540-545.
45. H1-specific variable region determinants recognized by anti-idiotypic monoclonal antibodies G6 and G8, Scan J Immunol 50 (1999), 14-20.
46. S. Suleyman, K.M. Thompson, R.A. Mageed and J.B. Natvig, Molecular analysis of human immunoglobulin heavy chain variable region associated determinants, Scand J Immunol 52 (2000), 341-347.
47. H1-associated cross-reactive idiotypes within IgMRF from patients with early synovitis, Ann Rheum Dis 49 (1990), 150-154.
48. H gene repertoire: Differential effects of selection and somatic hypermutation on human peripheral CD5+/IgM+ and CD5-/IgM+ B cells, J Clin Invest 99 (1997), 2488-2501.